JPWO2020219766A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020219766A5
JPWO2020219766A5 JP2021563234A JP2021563234A JPWO2020219766A5 JP WO2020219766 A5 JPWO2020219766 A5 JP WO2020219766A5 JP 2021563234 A JP2021563234 A JP 2021563234A JP 2021563234 A JP2021563234 A JP 2021563234A JP WO2020219766 A5 JPWO2020219766 A5 JP WO2020219766A5
Authority
JP
Japan
Prior art keywords
seq
raav
sequence
sequences
mirna target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530095A (ja
JP2022530095A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029642 external-priority patent/WO2020219766A1/en
Publication of JP2022530095A publication Critical patent/JP2022530095A/ja
Publication of JPWO2020219766A5 publication Critical patent/JPWO2020219766A5/ja
Publication of JP2022530095A5 publication Critical patent/JP2022530095A5/ja
Pending legal-status Critical Current

Links

JP2021563234A 2019-04-24 2020-04-23 レット症候群の治療に有用な組成物 Pending JP2022530095A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837947P 2019-04-24 2019-04-24
US62/837,947 2019-04-24
PCT/US2020/029642 WO2020219766A1 (en) 2019-04-24 2020-04-23 Compositions useful in treatment of rett syndrome

Publications (3)

Publication Number Publication Date
JP2022530095A JP2022530095A (ja) 2022-06-27
JPWO2020219766A5 true JPWO2020219766A5 (https=) 2023-04-28
JP2022530095A5 JP2022530095A5 (https=) 2023-04-28

Family

ID=72941315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563234A Pending JP2022530095A (ja) 2019-04-24 2020-04-23 レット症候群の治療に有用な組成物

Country Status (9)

Country Link
US (1) US20220202960A1 (https=)
EP (1) EP3973060A4 (https=)
JP (1) JP2022530095A (https=)
KR (1) KR20220003553A (https=)
CN (1) CN114026236A (https=)
AU (1) AU2020261051A1 (https=)
CA (1) CA3133889A1 (https=)
SG (1) SG11202111279QA (https=)
WO (1) WO2020219766A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230304034A1 (en) * 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
AU2022369293A1 (en) * 2021-10-18 2024-05-16 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
US20250312486A1 (en) * 2022-04-18 2025-10-09 City Of Hope Compositions for restoring mecp2 gene function and methods of use thereof
WO2024081551A1 (en) * 2022-10-10 2024-04-18 Passage Bio, Inc. Method of purifying full recombinant aav particles
EP4715058A1 (en) * 2023-05-15 2026-03-25 Genecombio Ltd. Gene therapy for rett syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069584A2 (en) * 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
PL2002003T3 (pl) * 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
PL2010563T3 (pl) * 2006-04-07 2011-11-30 Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej
US9415121B2 (en) * 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP3452101A2 (en) * 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CA3052487A1 (en) * 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JP7455579B2 (ja) * 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途
JP2020513831A (ja) * 2017-03-24 2020-05-21 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ エジンバラ MeCP2発現カセット
US11680275B2 (en) * 2017-06-06 2023-06-20 University Of Massachusetts Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome

Similar Documents

Publication Publication Date Title
JP7574508B2 (ja) 血管系を通過する遺伝子移入の方法および組成物
Daya et al. Gene therapy using adeno-associated virus vectors
JPWO2020132455A5 (https=)
JP2020537544A5 (https=)
JP6824169B2 (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
JP2018522529A5 (https=)
WO2016075473A2 (en) Factor ix gene therapy
FI3953377T3 (fi) Geeniterapioita lysosomaalisiin sairauksiin
JP2025539750A (ja) 前頭側頭型認知症の遺伝子治療
JPWO2020223231A5 (https=)
US20250163455A1 (en) Intron fragments
JPWO2021067448A5 (https=)
EP3924470A1 (en) Dual leucine zipper kinase inhibitors for gene therapy
KR20250115422A (ko) 반복적 요소의 적절한 패키징을 위한 아데노 연관 바이러스 벡터
JPWO2020219766A5 (https=)
AU2022282057B2 (en) Novel dual helper plasmid
JPWO2022036220A5 (https=)
JPWO2020227166A5 (https=)
JPWO2021231579A5 (https=)
WO2024220722A1 (en) Compositions and methods for tissue- specific expression of gene therapies
JPWO2022076803A5 (https=)
JPWO2021202817A5 (https=)
JPWO2021081217A5 (https=)
CA3219287C (en) Dual helper plasmid
JPWO2023086928A5 (https=)